[go: up one dir, main page]

RU2009112207A - Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью - Google Patents

Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью Download PDF

Info

Publication number
RU2009112207A
RU2009112207A RU2009112207/04A RU2009112207A RU2009112207A RU 2009112207 A RU2009112207 A RU 2009112207A RU 2009112207/04 A RU2009112207/04 A RU 2009112207/04A RU 2009112207 A RU2009112207 A RU 2009112207A RU 2009112207 A RU2009112207 A RU 2009112207A
Authority
RU
Russia
Prior art keywords
physiologically acceptable
compound
formula
acceptable solvate
pharmaceutical composition
Prior art date
Application number
RU2009112207/04A
Other languages
English (en)
Inventor
Кейт БИГГАДАЙК (GB)
Кейт Биггадайк
Дебора НИДХАМ (GB)
Дебора НИДХАМ
Original Assignee
Глаксо Груп Лимитед (GB)
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксо Груп Лимитед (GB), Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед (GB)
Publication of RU2009112207A publication Critical patent/RU2009112207A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1. Соединение формулы (I): ! ! или его физиологически приемлемый сольват. ! 2. Соединение формулы (I) по п.1 или его физиологически приемлемый сольват для применения в ветеринарии или в медицине человека. ! 3. Применение соединения формулы (I) по п.1 или его физиологически приемлемого сольвата для изготовления лекарства для лечения воспалительных и/или аллергических состояний. ! 4. Фармацевтическая композиция, содержащая соединение формулы (I) по п.1 или его физиологически приемлемый сольват, если требуется, в смеси с одним или более физиологически приемлемыми разбавителями или носителями. ! 5. Фармацевтическая аэрозольная композиция, содержащая соединение формулы (I) по п.1 или его физиологически приемлемый сольват и фторуглерод или водородсодержащий хлорфторуглерод в качестве пропеллента, возможно в комбинации с поверхностно-активным веществом и/или со-растворителем. ! 6. Фармацевтическая композиция по п.5, которая дополнительно содержит другой терапевтически активный агент. ! 7. Фармацевтическая композиция по п.6, в которой указанный другой терапевтически активный агент представляет собой агонист β2-адренорецепторов. ! 8. Способ лечения человека или животного с воспалительным и/или аллергическим состоянием, включающий введение указанному человеку или животному эффективного количества соединения формулы (I) по п.1 или его физиологически приемлемого сольвата.

Claims (8)

1. Соединение формулы (I):
Figure 00000001
или его физиологически приемлемый сольват.
2. Соединение формулы (I) по п.1 или его физиологически приемлемый сольват для применения в ветеринарии или в медицине человека.
3. Применение соединения формулы (I) по п.1 или его физиологически приемлемого сольвата для изготовления лекарства для лечения воспалительных и/или аллергических состояний.
4. Фармацевтическая композиция, содержащая соединение формулы (I) по п.1 или его физиологически приемлемый сольват, если требуется, в смеси с одним или более физиологически приемлемыми разбавителями или носителями.
5. Фармацевтическая аэрозольная композиция, содержащая соединение формулы (I) по п.1 или его физиологически приемлемый сольват и фторуглерод или водородсодержащий хлорфторуглерод в качестве пропеллента, возможно в комбинации с поверхностно-активным веществом и/или со-растворителем.
6. Фармацевтическая композиция по п.5, которая дополнительно содержит другой терапевтически активный агент.
7. Фармацевтическая композиция по п.6, в которой указанный другой терапевтически активный агент представляет собой агонист β2-адренорецепторов.
8. Способ лечения человека или животного с воспалительным и/или аллергическим состоянием, включающий введение указанному человеку или животному эффективного количества соединения формулы (I) по п.1 или его физиологически приемлемого сольвата.
RU2009112207/04A 2003-07-11 2009-04-03 Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью RU2009112207A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316290.6A GB0316290D0 (en) 2003-07-11 2003-07-11 Novel compounds
GB0316290.6 2003-07-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2005141226/04A Division RU2359973C2 (ru) 2003-07-11 2004-07-09 Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью

Publications (1)

Publication Number Publication Date
RU2009112207A true RU2009112207A (ru) 2010-10-10

Family

ID=27742019

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2005141226/04A RU2359973C2 (ru) 2003-07-11 2004-07-09 Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью
RU2005141064/04A RU2348645C2 (ru) 2003-07-11 2004-07-09 Специфическое глюкокортикостероидное соединение, обладающее противовоспалительной активностью
RU2009112207/04A RU2009112207A (ru) 2003-07-11 2009-04-03 Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью

Family Applications Before (2)

Application Number Title Priority Date Filing Date
RU2005141226/04A RU2359973C2 (ru) 2003-07-11 2004-07-09 Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью
RU2005141064/04A RU2348645C2 (ru) 2003-07-11 2004-07-09 Специфическое глюкокортикостероидное соединение, обладающее противовоспалительной активностью

Country Status (30)

Country Link
US (6) US7291609B2 (ru)
EP (3) EP1644397B1 (ru)
JP (3) JP4709752B2 (ru)
KR (2) KR101075324B1 (ru)
CN (3) CN1845933B (ru)
AR (2) AR045901A1 (ru)
AT (1) ATE467638T1 (ru)
AU (2) AU2004255854B2 (ru)
BR (2) BRPI0412527A (ru)
CA (2) CA2531905C (ru)
CY (2) CY1110149T1 (ru)
DE (1) DE602004027137D1 (ru)
DK (2) DK1644397T3 (ru)
ES (3) ES2433665T3 (ru)
GB (1) GB0316290D0 (ru)
HR (2) HRP20130056T1 (ru)
IL (3) IL172777A (ru)
IS (3) IS2909B (ru)
MA (2) MA27897A1 (ru)
MX (2) MXPA06000443A (ru)
MY (2) MY140987A (ru)
NO (2) NO333263B1 (ru)
NZ (2) NZ544576A (ru)
PL (2) PL1644398T3 (ru)
PT (2) PT1644397E (ru)
RU (3) RU2359973C2 (ru)
SI (2) SI1644398T1 (ru)
TW (2) TWI338694B (ru)
WO (2) WO2005005451A1 (ru)
ZA (2) ZA200600223B (ru)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0125259D0 (en) * 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0316290D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004025966A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estradiol-Prodrugs
DE102004025985A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estriol- und Estetrol-Prodrugs
US20090124588A1 (en) * 2005-01-10 2009-05-14 Glaxo Group Limited Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions
WO2006072599A2 (en) * 2005-01-10 2006-07-13 Glaxo Group Limited Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions
US20090298802A1 (en) * 2005-03-30 2009-12-03 Sequeira Joel A Pharmaceutical Compositions
US7829554B2 (en) 2005-07-14 2010-11-09 Lithera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
MX2008013411A (es) 2006-04-20 2008-11-04 Glaxo Group Ltd Nuevos compuestos.
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
WO2008048770A1 (en) * 2006-10-17 2008-04-24 Lipothera, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
MX2010012814A (es) 2008-05-23 2010-12-20 Amira Pharmaceuticals Inc Inhibidor de proteina activadora de 5-lipoxigenasa.
WO2009147187A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
US20120058984A1 (en) 2009-03-17 2012-03-08 Catherine Mary Alder Pyrimidine derivatives used as itk inhibitors
WO2010107952A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120016010A1 (en) 2009-03-19 2012-01-19 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of BTB and CNC Homology 1, Basic Leucine Zipper Transcription Factor 1 (BACH1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20120035247A1 (en) 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
EP2411019A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
KR20110138223A (ko) 2009-03-27 2011-12-26 머크 샤프 앤드 돔 코포레이션 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
US20120022143A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
AR076373A1 (es) 2009-04-24 2011-06-08 Glaxo Group Ltd N-pirazolil carboxamidas como inhibidores de canales de calcio
JP2012524754A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド Ｃｒａｃチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
PL2899191T3 (pl) 2009-04-30 2018-01-31 Glaxo Group Ltd Indazole podstawione oksazolem jako inhibitory kinazy PI3
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
CN102448978A (zh) 2009-05-29 2012-05-09 辉瑞有限公司 新颖的糖皮质激素受体激动剂
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
CN102869363A (zh) * 2010-01-15 2013-01-09 利赛拉公司 冻干的块状制剂
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
HUE026059T2 (en) 2010-09-08 2016-05-30 Glaxosmithkline Ip Dev Ltd N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazol-6-yl ] Polymorphs and salts of 2 - (methyloxy) -3-pyridinyl] methanesulfonamide
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
WO2012052458A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
US9149462B2 (en) 2010-10-21 2015-10-06 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US9597531B2 (en) 2010-11-24 2017-03-21 Neothetics, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
EP2683716A1 (en) 2011-03-11 2014-01-15 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
US10155001B2 (en) 2013-06-14 2018-12-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) RAC1 inhibitors for inducing bronchodilation
CA2923995A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
WO2015055691A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
TW201625247A (zh) 2014-05-12 2016-07-16 葛蘭素史密斯克藍智慧財產權有限公司 用於治療傳染性疾病之醫藥組合物
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
KR102712798B1 (ko) 2017-11-21 2024-10-04 씨에스 파마슈티컬스 리미티드 안구주위 분비선 또는 안구 표면에서의 이상 염증을 치료하기 위한 조성물 및 사용 방법
US11759472B2 (en) 2017-11-21 2023-09-19 Cs Pharmaceuticals Limited Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
WO2021191875A1 (en) 2020-03-26 2021-09-30 Glaxosmithkline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections
JP2026501523A (ja) * 2023-01-10 2026-01-16 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド グルココルチコイド受容体アゴニスト及びそのコンジュゲート

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2856828A (en) * 1955-01-24 1958-10-21 Leukart Machine Co Inc J Impacting machine
US3943124A (en) * 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
GB1384372A (en) * 1971-01-20 1975-02-19 Glaxo Lab Ltd Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids
US3686978A (en) 1971-04-09 1972-08-29 Fairfied Mfg Co Inc Plantetary reduction wheel hub
GB1438940A (en) * 1972-07-19 1976-06-09 Glaxo Lab Ltd 17beta-haloalkoxycarbonyl-17alpha-oxysteroids
GB1514476A (en) 1974-08-30 1978-06-14 Glaxo Lab Ltd Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates
US4093721A (en) * 1974-08-30 1978-06-06 Glaxo Laboratories Limited Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof
GB2137206B (en) 1980-02-15 1985-04-03 Glaxo Group Ltd Androstane 17-carbothioc acid derivatives
SE449106B (sv) 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
US4996335A (en) * 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
ATE90355T1 (de) 1987-10-13 1993-06-15 Nicholas S Bodor Weiche steroide mit anti-entzuendungswirkung.
US5990099A (en) 1988-10-31 1999-11-23 Alcon Laboratories, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
HU225869B1 (en) * 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
ATE191470T1 (de) 1994-06-15 2000-04-15 Wellcome Found Enzymhemmer
US6172054B1 (en) * 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
WO1997041867A1 (en) 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Use of steroid compounds to prevent non-cancerous tissue growth
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
US6245804B1 (en) * 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
US6395738B1 (en) 1997-10-01 2002-05-28 Kyowa Hakko Kogyo Co., Ltd. Benzofuran derivatives
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
JP2002506856A (ja) 1998-03-14 2002-03-05 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング フタラジノンｐｄｅｉｉｉ／ｉｖ阻害剤
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
CN1353717A (zh) 1999-05-04 2002-06-12 莱加制药公司 四环黄体酮受体调节剂化合物及其方法
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6263209B1 (en) 1999-07-28 2001-07-17 Motorola, Inc. Method and apparatus in a wireless communication system for creating a learning function
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds
KR100889426B1 (ko) * 2000-08-05 2009-03-23 글락소 그룹 리미티드 항염증제로서의 6.알파.,9.알파.-디플루오로-17.알파.-'(2-푸라닐카르복실)옥시-11.베타.-히드록시-16.알파.-메틸-3-옥소-안드로스트-1,4-디엔-17-카르보티오산 ｓ-플루오로메틸 에스테르
NZ525056A (en) 2000-09-29 2004-11-26 Glaxo Group Ltd Morpholin-acetamide derivatives for the treatment of inflammatory diseases
EP1341541A4 (en) 2000-11-16 2004-11-17 Alcon Mfg Ltd COMBINATION THERAPY FOR LOWERING AND CONTROLLING THE EYE PRESSURE
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ　グループ　リミテッド βアドレナリン受容体のアゴニスト
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
AU2002253342B2 (en) * 2001-04-30 2007-01-04 Glaxo Group Limited Novel anti-inflammatory androstane derivatives
AU2002326026B2 (en) 2001-09-14 2005-04-28 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
GB0125259D0 (en) * 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
JP2005519897A (ja) 2002-01-14 2005-07-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックス、その製造方法、それを含む医薬製剤及びその使用
WO2003072592A1 (en) * 2002-01-15 2003-09-04 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
WO2003061651A1 (en) 2002-01-22 2003-07-31 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
US7268152B2 (en) 2002-03-26 2007-09-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
KR101022977B1 (ko) 2002-03-26 2011-03-18 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 글루코코르티코이드 모사체, 이의 제조방법, 약제학적조성물 및 이의 용도
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
US6897224B2 (en) 2002-04-02 2005-05-24 Schering Ag Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
US7282591B2 (en) 2002-04-11 2007-10-16 Merck & Co., Inc. 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
ATE381535T1 (de) 2002-04-25 2008-01-15 Glaxo Group Ltd Phenethanolaminderivate
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
BR0312575A (pt) 2002-07-08 2005-05-03 Pfizer Prod Inc Moduladores do receptor de glicocorticóides
AU2003251970A1 (en) 2002-07-18 2004-02-09 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7442554B2 (en) 2002-07-18 2008-10-28 Bristol-Myers Squibb Company Compositions and methods involving glucocorticoid receptor site II
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
DE60322713D1 (de) 2002-08-21 2008-09-18 Boehringer Ingelheim Pharma Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
CN100387598C (zh) 2002-09-16 2008-05-14 葛兰素集团有限公司 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
JP4520309B2 (ja) 2002-09-20 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション 選択的糖質コルチコイド受容体調節剤としてのオクタヒドロ−２−Ｈ−ナフト［１，２−ｆ］インドール−４−カルボキサミド誘導体
JP2006506373A (ja) 2002-10-22 2006-02-23 グラクソ　グループ　リミテッド 医薬アリールエタノールアミン化合物
AU2003286143A1 (en) 2002-10-28 2004-05-13 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
MXPA06000442A (es) 2006-04-07
TWI338694B (en) 2011-03-11
IS8193A (is) 2005-12-22
TW200524953A (en) 2005-08-01
PT1644398E (pt) 2013-03-05
EP2380898A1 (en) 2011-10-26
IL172777A0 (en) 2006-04-10
ATE467638T1 (de) 2010-05-15
ES2400821T3 (es) 2013-04-12
US7291609B2 (en) 2007-11-06
NZ544577A (en) 2009-07-31
HK1089186A1 (en) 2006-11-24
RU2005141064A (ru) 2006-08-10
CN1845933A (zh) 2006-10-11
JP4709751B2 (ja) 2011-06-22
WO2005005451A1 (en) 2005-01-20
DE602004027137D1 (de) 2010-06-24
HRP20130056T1 (hr) 2013-02-28
JP2009514781A (ja) 2009-04-09
AU2004255855A1 (en) 2005-01-20
EP1644397A1 (en) 2006-04-12
CA2531911A1 (en) 2005-01-20
ZA200600223B (en) 2007-04-25
CA2531911C (en) 2011-11-01
MA27897A1 (fr) 2006-05-02
US20080015360A1 (en) 2008-01-17
NO20060110L (no) 2006-02-09
NO20060111L (no) 2006-01-24
RU2359973C2 (ru) 2009-06-27
JP4709752B2 (ja) 2011-06-22
IS2928B (is) 2015-09-15
HRP20100359T1 (hr) 2010-07-31
SI1644397T1 (sl) 2010-09-30
ZA200600226B (en) 2007-04-25
CN1849330A (zh) 2006-10-18
MY137944A (en) 2009-04-30
AR045900A1 (es) 2005-11-16
US7288536B2 (en) 2007-10-30
AU2004255854A1 (en) 2005-01-20
BRPI0412526A (pt) 2006-09-19
US20100152148A1 (en) 2010-06-17
IS8194A (is) 2005-12-22
IL172776A (en) 2015-05-31
MXPA06000443A (es) 2006-04-07
ES2343685T3 (es) 2010-08-06
AR045901A1 (es) 2005-11-16
EP2380898B1 (en) 2013-08-28
GB0316290D0 (en) 2003-08-13
CN102372756A (zh) 2012-03-14
TW200524954A (en) 2005-08-01
JP2009513533A (ja) 2009-04-02
IS2909B (is) 2014-11-15
AU2004255854B2 (en) 2009-10-22
IS050094A (is) 2014-10-28
US20080070880A1 (en) 2008-03-20
RU2005141226A (ru) 2006-08-27
BRPI0412527A (pt) 2006-09-19
EP1644398B1 (en) 2013-01-09
MY140987A (en) 2010-02-12
CN1849330B (zh) 2011-05-25
RU2348645C2 (ru) 2009-03-10
EP1644397B1 (en) 2010-05-12
NO332041B1 (no) 2012-06-11
WO2005005452A1 (en) 2005-01-20
IL210209A0 (en) 2011-03-31
PL1644398T3 (pl) 2013-05-31
US7524970B2 (en) 2009-04-28
PL1644397T3 (pl) 2010-10-29
IL172777A (en) 2012-05-31
TWI367888B (en) 2012-07-11
CY1113836T1 (el) 2016-07-27
IS2776B (is) 2012-03-15
CA2531905C (en) 2012-05-08
MA27899A1 (fr) 2006-05-02
SI1644398T1 (sl) 2013-04-30
CY1110149T1 (el) 2015-01-14
HK1089185A1 (en) 2006-11-24
US20060247219A1 (en) 2006-11-02
KR20060052801A (ko) 2006-05-19
CA2531905A1 (en) 2005-01-20
JP2011093929A (ja) 2011-05-12
DK1644397T3 (da) 2010-08-23
ES2433665T3 (es) 2013-12-12
KR20060052807A (ko) 2006-05-19
KR101029207B1 (ko) 2011-04-12
NZ544576A (en) 2009-06-26
DK1644398T3 (da) 2013-02-04
KR101075324B1 (ko) 2011-10-19
IL172776A0 (en) 2006-04-10
US20070043007A1 (en) 2007-02-22
US7638508B2 (en) 2009-12-29
NO333263B1 (no) 2013-04-22
PT1644397E (pt) 2010-07-01
US20080021231A1 (en) 2008-01-24
AU2004255855B2 (en) 2009-07-30
EP1644398A1 (en) 2006-04-12
CN1845933B (zh) 2011-10-05

Similar Documents

Publication Publication Date Title
RU2009112207A (ru) Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью
RU2384580C2 (ru) Ингибиторы фосфатидилинозитол-3-киназы
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
BRPI0113042B8 (pt) composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
KR19990044182A (ko) 말초 활성 통각과민 치료용 아편제
AR022461A1 (es) Compuesto de 5-hidroxiindol sustituido; proceso para su preparacion y composicion farmaceutica que lo contiene
ATE318598T1 (de) Antioxidierende stabilisierungssysteme für pharmazeutische formulierungen
DK1392329T3 (da) Anvendelse af sulodexid til behandling af inflammatorisk tarmsygdom
JP2011500779A (ja) 新規製剤
RU2002132882A (ru) Кожные композиции, содержащие кофермент q в качестве активного ингредиента
DK0969843T3 (da) Antitussive formuleringer indeholdende theobromin
ES2184145T3 (es) Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida.
DE60129829D1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
JP2003528919A5 (ru)
RU2006138495A (ru) Использование агонистов рецепторов, активируемых пролифератором пероксисомы дельта для лечения рс и других демиелинизирующих заболеваний
CN101400261B (zh) 使用三唑化合物治疗炎症异常
BRPI0407335A (pt) Agentes antibacterianos
KR970706811A (ko) I형 알레르기성 질환의 예방 및 치료제(Preventive and remedy for type Ⅰ allergic diseases)
JP2008540534A (ja) 放出調節薬学組成物
TR200103144T2 (tr) Yeni bileşikler
AR015761A1 (es) Un derivado del acido 2-metilpropionico,una composicion farmaceutica que lo incluye, uso de un derivado del acido 2-metilpropionico y un procedimiento parala fabricacion de una composicion farmaceutica para la prevencion o el tratamiento de enfermedades
WO2005007140A1 (en) Pharmaceutical composition containing insect repellent
Flint et al. Griseofulvin, a new oral antibiotic for the treatment of fungous infections of the skin

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20120514